Previous studies have reported that serum myostatin levels are significantly elevated in patients with end-stage liver disease or sarcopenia, and are associated with poorer survival in cirrhotic patients compared with those who had low serum myostatin levels [9,12,13]. Here, MSTN is linked to sarcopenia.